VERVE-102
VERVE-102gene therapyLNP-delivered base editor targeting PCSK9
Familial Hypercholesterolemia
Phase 2
1 program·1 trial·View drug →
DashboardSell497,016$15.83−$7.9MSell18,491$17.22−$318.4KSell23,004$16.13−$371.1KBuy5,358$12.24+$65.6KSell544,977$15.59−$8.5MBuy21,144$16.24+$343.4KSell24,016$15.57−$373.9K HepatologyCo-Investigator$498.2K7HepatologyResearch Grant$380.9K3GastroenterologyEquity / Ownership$261.1K3GastroenterologyCo-Investigator$259.6K2GastroenterologyResearch Grant$245.5K7GastroenterologyResearch Grant$204.4K2HepatologyResearch Grant$192.2K6GastroenterologyResearch Grant$105.1K2HepatologyResearch Grant$89.9K2
VERVNASDAQ
Verve Therapeutics
Verve Therapeutics, Inc. · Boston, MA · founded 2018
Verve Therapeutics is a Boston biotech developing one-time gene-editing treatments for cardiovascular disease. The lead candidate uses base editing delivered via lipid nanoparticles to permanently turn off the PCSK9 gene in liver cells, lowering LDL cholesterol; a second program targets ANGPTL3 to reduce both LDL and triglycerides. The intent is a single intravenous infusion that provides decades of cholesterol-lowering effect.
- Lead asset
- VERVE-102 · Ph2 · Familial Hypercholesterolemia
- gene therapy · LNP-delivered base editor targeting PCSK9
- Pipeline
- 1 drug · 1 program
- 1 Cardio-Renal
- Modalities
- gene therapy×1
FocusGene TherapyCardio-Renal
$7.30-17.33%1Y
VERV · daily close · illustrative · 1 catalyst marked
Conf.-5%
1Y high$9.081Y low$6.96range$2.12(30%)past catalysts
Peers in this space
ALNY$33.2B
Alnylam
Rel.
0.65
Cardio-RenalsiRNA
1 programmatch: sector
IONS$5.8B
Ionis
Rel.
0.62
Cardio-Renaloligonucleotide
1 programmatch: sector
ARWR$2.2B
Arrowhead Pharmaceuticals
Rel.
0.46
Cardio-RenalsiRNA
1 programmatch: sector
ARDX$1.7B
Ardelyx
Rel.
0.61
Cardio-Renalsmall molecule
1 programmatch: sector
SRPT$2.8B
Sarepta Therapeutics
Rel.
0.47
Rare Diseasegene therapy
1 programmatch: modality
NTLA$1.9B
Intellia
Rel.
0.31
Immunologygene therapy
1 programmatch: modality
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph21
- Ph30
- Filed0
- Approved0
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Nov 26, 2025Conf.VERVE-102 — ASH Late-Breaker — Updated SurvivalMixed-4.8%+6.5%+9.7%
Dec 31, 2024Enroll.VERVE-102 — Pivotal Enrollment CompletePositive+6.7%+4.5%+6.0%
Aug 3, 2024AdComVERVE-102 — Advisory Committee — 12–2 Vote in FavorPositive+25.4%+28.8%+18.8%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 7 transactions · 7 insiders
Net flow
−$17.0M
Buys
$409.0K
2 txns
Sells
$17.4M
5 txns
Largest
−$8.5M
10% Owner sell
Net flow per quarter · last 8Q
9 txns · sum −$17.73M
24Q325Q125Q326Q126Q2
buys · $409Ksells · $18.14M
Insider · roleActionSharesPriceValueDate
R. Chen
10% Owner
Apr 22, 2026
S. Kowalski
EVP
Apr 11, 2026
E. Morais
COO
Apr 3, 2026
T. Schwarz
Director
Mar 28, 2026
C. Kowalski
10% Owner
Mar 18, 2026
R. Goldstein
EVP
Mar 15, 2026
K. Park
EVP
Mar 11, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
3 trades · 3 members
Est. net flow
−$1.13M
midpoint · brackets only
Buys
0
Sells
3
Party mix
1 D1 R1 I
Member · chamberActionBracket~ midpointOwnerDate · disclosure
I
Sell$250K–$500K~$375KselfSen. F. Park
Senate · ME
Feb 24, 2026
filed +44d
R
Partial sell$500K–$1.00M~$750KselfSen. D. Greenwood
Senate · TX
Aug 10, 2025
filed +17d
D
Sell$1K–$15K~$8KselfRep. K. Linville
House · WA
Apr 28, 2025
filed +11d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
4 ETFs hold the position
Held by ETFs
$29.5M
aggregate position
Of market cap
5.47%
aggregate ETF share
Top holder
ARKG1.58%
ARK Genomic Revolution ETF
TickerETF · familyThemeNAV% of NAVPosition
ARKGGene editing$1.20B1.58%$19.0M
ARK Genomic Revolution ETF
ARK
IDNAGenomics$200.0M4.10%$8.2M
iShares Genomics Immunology Healthcare
iShares
GNOMGenomics$90.0M2.30%$2.1M
Global X Genomics & Biotechnology
VanEck
PBEBroad biotech$175.0M0.18%$315K
Invesco Dynamic Biotechnology
Invesco
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
9 physicians paid · 34 disclosed records
Total 2025+2024
$2.24M
YoY
-7%
Research Grant$1.15MCo-Investigator$558.9KEquity / Ownership$376.0KSpeaking$68.9KConsulting$64.7KTravel & Lodging$20.9KFood & Beverage$717
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. James Goldstein
NYU Langone
Dr. Elena Park
Vanderbilt
Dr. Yuki Chen
Mass General Hospital
Dr. Olivia Walsh
MD Anderson
Dr. Devon Park
Memorial Sloan Kettering
Dr. Nadia Patel
Vanderbilt
Dr. Priya Iyer
UCSF
Dr. Charles Fischer
University of Washington
Dr. Kavya Reyes
Duke University
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$136K disclosed · 2 firms engaged
YoY change
+11%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Van Scoyoc Associates$81K
6 quarters active
Cassidy & Associates$56K
5 quarters active
Top issues lobbied
- Patent Trial and Appeal Board reforms$96K
- Inflation Reduction Act drug-price negotiation$40K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
1 award · 1 agency
Total awarded
$12.3M
across all programs
Active
$0
option periods incl.
Top agency
NIH / NHLBI$12.3M
AgencyTitle · type · award IDStatusValueAwarded → ends
NIH / NHLBIcompleted$12.3MJun 2023→ Dec 2024
Cardiovascular Outcomes Trial Co-Funding
Cooperative Agreement · NIH-67418468
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
2 granted · 1 pending
Total in portfolio
3
Granted in last 12mo
0
Expiring < 2yr
0
Nearest expiry
Apr 2029
Patent #Title · inventor · drugTypeStatus · filedExpiry
US 2026/9966655 A1Composition of Matter
Modified RNA constructs and methods of use thereof VERVE-102
J. Müller + 2 · VERVE-102
pendingfiled Apr 2026
in prosecution
12,365,392Method of Use
Pediatric methods of use for VERVE-102
T. Patel + 4 · VERVE-102
grantedfiled Apr 2018
exp. Apr 2038
12.0y left
11,655,474Composition of Matter
Modified RNA constructs and methods of use thereof VERVE-102
N. Kowalski + 2 · VERVE-102
grantedfiled Apr 2009
exp. Apr 2029
3.0y left
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
10 items from 5 categories
clinical3partnership3regulatory2analyst1earnings1
just now
Sell-side raises price target on VERV after pipeline review
Reuters·analyst
7d ago
EMA validates VERV's Marketing Authorization Application for VERVE-102
PR Newswire·regulatory
14d ago
VERV presents VERVE-102 data at major medical conference
FierceBiotech·clinical
15d ago
VERV reports Q1 financial results and pipeline update
Business Wire·earnings
17d ago
VERV enters licensing agreement with major pharma for VERVE-102
PR Newswire·partnership
18d ago
VERV doses first patient in Phase 3 VERVE-102 study
FierceBiotech·clinical
21d ago
VERV completes enrollment in VERVE-102 Phase 2 trial
Endpoints News$·clinical
29d ago
VERV enters licensing agreement with major pharma for VERVE-102
PR Newswire·partnership
1mo ago
EMA validates VERV's Marketing Authorization Application for VERVE-102
Endpoints News$·regulatory
1mo ago
VERV closes ex-U.S. rights deal worth $3.7 billion in milestones
Business Wire·partnership
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$7.30
Open
$7.29
Day Δ
+0.01
+0.14%
Day range
$7.23 – $7.36
52W range
$6.96 – $9.08
Avg daily volume
562K
Valuation & ownership
Enterprise value
$282M
Shares out
73.97M
Float
71.01M
Insider %
14.63%
Institutional %
79.63%
Beta
2.13
vs SPY · 52w
Balance sheet & burn
Cash + invest
$464M
Total debt
$163M
Debt / equity
5.63
Cash burn / Q
$48M
R&D spend TTM
$182M
39% of cash
ATM available
None
no active facility
Earnings
EPS latest
$-0.88
EPS Δ vs prior
+0.03
EPS estimate
$-0.75
next quarter
EPS prior
$-0.91
Next earnings
Jun 10, 2026
Rev guidance
$15M